Symbicort Onset of Action 2

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: albuterol; Drug: budesonide/formoterol; Drug: fluticasone/salmeterol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00646009

D5896C00733

SD-039-0733

Details and patient eligibility

About

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Enrollment: 48 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age
• Diagnosis of asthma and baseline lung function test results as determined by the protocol
• Required and received inhaled corticosteroids within timeframe and doses specified in the protocol

Exclusion criteria

• Severe asthma or asthma that is markedly effected by seasonal factors
• Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

48 participants in 3 patient groups

1

Experimental group

Description:

budesonide/formoterol

Treatment:

Drug: budesonide/formoterol

2

Active Comparator group

Description:

fluticasone/salmeterol

Treatment:

Drug: fluticasone/salmeterol

3

Active Comparator group

Description:

albuterol

Treatment:

Drug: albuterol